Imprimis Pharmaceuticals Inc., of San Diego, reported for the second quarter that its revenues were $10.4 million, up 51 percent year-over-year with gross ophthalmology-related revenue of $8.3 million, up 74 percent. Net income for the period was $2.5 million. Shares of Imprimis (NASDAQ:IMMY) closed at $2.71, up 25 cents, on Tuesday.